Results 61 to 70 of about 371,080 (288)
Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues
ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang +7 more
wiley +1 more source
Acta Biomedica Scientifica, 2012 The aim. was to study peculiarities of ischemic and idiopathic dilated cardiomyopathy and. aggregative activity of thrombocytes and. also the response to the therapy by beta-blockers (Atenolol and Bisoprolol). Material and.
P. N. Isakhanova, Yu. N. Ziyaev
doaj
Factors determining quality of life of patients with ischemic cardiomyopathy selected for revascularization procedures [PDF]
, 2016 The aim – to evaluate the determinants of quality of life (QoL) of patients with ischemic cardiomyopathy selected for coronary artery bypass grafting or coronary stenting. Materials and methods.
B.М. Тоdurov +4 more
core
Forecasting heart failure: Seasonal alignment of heart failure outcomes in New York
ESC Heart Failure, Volume 12, Issue 2, Page 819-831, April 2025.Abstract Background Seasonal variations have been observed in heart failure (HF) hospitalization. Numerous explanatory mechanisms have been proposed, but no prior studies have examined potential contributors directly. Our objective was to identify specific factors that could contribute to seasonal variability using a large longitudinal dataset of HF ...
Prerna Gupta +5 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler +4 more
wiley +1 more source
Molecular genetics of arrhythmogenic right ventricular cardiomyopathy in South Africa [PDF]
, 2011 Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a heritable disorder characterised by progressive degeneration of the right ventricular myocardium, arrhythmias and an increased risk of sudden death at a young age. Fourteen chromosomal loci have
Blanckenberg, Janine
core +1 more source
Criteria of eligibility of patients with ischemic cardiomyopathy for revascularization and other surgical procedures [PDF]
, 2016 The aim of this review is to summarize contemporary approaches to the management of ischemic cardiomyopathy taking into consideration myocardial viability and geometric changes of left ventricle (LV). Information about methods of viability assessment and
N.D. Oryshchyn
core
ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya +9 more
wiley +1 more source
The Egyptian Heart Journal, 2014 Left atrial (LA) contractility plays an important role in maintenance of cardiac output in patients with left ventricular systolic dysfunction. Although left atrial contractile dysfunction has been reported in dilated cardiomyopathy of ischemic and non ...
Mohammad Abdulghani Abdulzaher +4 more
doaj +3 more sources
ESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou +7 more
wiley +1 more source